GNOM
Closed
Global X Genomics & Biotechnology Etf
8.48
+0.05 (+0.59%)
Last Update: 01 Jul 2025 23:15:00
Yesterday: 8.43
Day's Range: 8.355 - 8.64
Send
sign up or login to leave a comment!
When Written:
12.1901
The Global X Genomics & Biotechnology ETF (GNOM) is an exchange-traded fund that invests in companies involved in the genomics and biotechnology industries. The fund seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index.
The fund invests in companies that are involved in gene editing, gene sequencing, genetic therapies, and other biotechnology applications. It is designed to provide investors with exposure to companies that are at the forefront of medical research and development.
As of May 2021, the fund has total net assets of over $1.4 billion and holds over 40 different stocks in its portfolio. The top holdings of the fund include Illumina Inc., Thermo Fisher Scientific Inc., and Moderna Inc.
The GNOM ETF has an expense ratio of 0.68%, which is relatively low compared to other actively managed funds in the biotech and genomics space. It is an attractive option for investors looking to gain exposure to the rapidly growing biotech industry.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The fund invests in companies that are involved in gene editing, gene sequencing, genetic therapies, and other biotechnology applications. It is designed to provide investors with exposure to companies that are at the forefront of medical research and development.
As of May 2021, the fund has total net assets of over $1.4 billion and holds over 40 different stocks in its portfolio. The top holdings of the fund include Illumina Inc., Thermo Fisher Scientific Inc., and Moderna Inc.
The GNOM ETF has an expense ratio of 0.68%, which is relatively low compared to other actively managed funds in the biotech and genomics space. It is an attractive option for investors looking to gain exposure to the rapidly growing biotech industry.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!